Diagnostic Center | March 23, 2024
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
With this, the total number of Patents granted to company for its innovative processes and technology stands at 9
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Subscribe To Our Newsletter & Stay Updated
